SOPHiA GENETICS and AstraZeneca collaborate to develop two CDx in Boston and Rolle; decentralized CDx deployment worldwide
SOPHiA GENETICS and AstraZeneca collaborate to develop two CDx in Boston and Rolle; decentralized CDx deployment worldwide SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies - SOPHiA GENETICS SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies BOSTON and ROLLE – August 4, 2026 – SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE ...